All News

A novel agent is attacking a newly found target in patients with acute myeloid leukemia (AML).

Jonathan E. Rosenberg, M.D., discusses the implications of the new treatment guidelines for muscle-invasive bladder cancer.

Coping with losses, one lesson at a time

Studies look at women with peripheral neuropathy after treatment for early-stage breast cancer

Chemo fog, or chemo brain, is a very real phenomena that cancer survivors need to be knowledgeable about. This describes the journey of one survivor.

Although they bring devastation to the whole community hit, catastrophes, such as Tropical Storm Harvey and Hurricane Irma, introduce a new level of difficulty for patients who are being treated for cancer.

RET rearrangements, while they only occur in about 1 percent of patients with non-small cell lung cancer, are nevertheless an important biomarker to identify, since targeted agents have proven to be beneficial in this patient population, and realizing a patient has the mutation can greatly impact their treatment plan, says Christine M. Lovly, M.D., Ph.D.

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

Aromatase inhibitors cause unwanted side effects. More and more women are choosing not to take them, but is this a good idea?

Survivor shares that there is no shame to talk to a therapist about life’s difficulties, especially when those difficulties have included coping with a cancer diagnosis and the ongoing fear of recurrence.

David R. Gandara, M.D., discusses the latest immunotherapy advances in lung cancer, as well as the next steps toward optimizing the use of these agents.

Kymriah, a CAR T-cell therapy, was approved to treat certain pediatric and young adult patients who have acute lymphoblastic leukemia (ALL).

Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).

Sometimes the person you share your life with can help save yours.

Cancer has a silver lining, too. Breast cancer and melanoma survivor shares hers.

It's not really over, when it's "over."

Oncology care centers in Tropical Storm Harvey’s path close down locations, provide off-site care and update patients via their websites and social media.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.

If you're a writer who has had cancer, you won't be running out of story ideas any time soon.

We can all learn some things from an extraordinary young man.

The flood in Texas is causing strife for thousands of people. But patients with cancer have additional stressors.

Reach out now to your friend with cancer.

The Food and Drug Administration (FDA) approved Faslodex (fulvestrant) to treat patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in postmenopausal women who were not treated with endocrine therapy.

The facts are in on stress reduction, and many doctors still are not taking advantage of the benefits.

A male breast cancer survivor ponders the power of attitude.

Life with cancer, like life in general, gives us plenty of chances to practice being grateful.

We’re moving into a new era of understanding with genetic abnormalities in colorectal cancer (CRC) as researchers continue to investigate tumor sidedness and the role of microsatellite instability (MSI) testing.